Visual prognosis based staging for retinal capillary hemangioma
https://doi.org/10.21516/2072-0076-2020-13-2-12-17
Abstract
Purpose. To analyze the literature to determine the visual prognosis of eyes affected by retinal angiomatosis of Von-Hippel Lindau disease (VHL). Study Type. Retrospective literature analysis. Methods. Medline and PubMed searches were performed for publications on retinal capillary hemangioma (CRH). Data was collected on patient age of presentation, CRH laterality, location, treatment, and progression. Statistical analyses using Pearson Chi-Square test, likelihood ratio, and Fischer’s exact tests were performed for the effect of these characteristics on visual acuity outcomes. Results. Vision outcomes need to be based on current technology to be clinically relevant. Therefore, only significant publications from 1960 to 2019 were included. Of these, 5 clinical case series included, a total of 427 cases. Of these 69.4 % (58–94.1 %) cases were unilateral CRH, 30.6 % (5.9–42 %) were bilateral, 18.1 % (10.9–23.5 %) were juxtapapillary in location. Major factors affecting visual acuity were age at onset (p = 0.03), location (p < 0.0001) and multifocality (p = 0.0005). Of interest, CRH-related vision loss was independent of the presence of VHL disease (p = 0.157). Conclusion. In this study, age at onset, location, multifocality of CRH were the most important predictors of vision loss, which were used to create a vision-outcome based classification system. This information can be used to counsel patients and for informed consent.
About the Authors
G. Garg
New York Eye Cancer Center
United States
United States
Gaurav Garg — Fellow, Dept. of Ocular Tumor, Orbital Disease, Ophthalmic Radiation
115, East 61st Street , New York, NY 10065
P. T. Finger
New York Eye Cancer Center
United States
United States
Paul T. Finger — Professor of Ophthalmology at the New York University School of Medicine and Director of Ocular Oncology, The New York Eye Cancer Center
115, East 61st Street , New York, NY 10065
References
1. Maher E.R., Yates J.R., Harries R., et al. Clinical features and natural history of von Hippel – Lindau disease. Q. J. Med. 1990 Nov; 77 (283): 1151–63.
2. Retinal hemangioblastoma. A histologic, immunohistochemical, and ultrastructural evaluation. Available at: https://www.ncbi.nlm.nih.gov/pubmed/1741127
3. Webster A.R., Maher E.R., Moore A.T. Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch. Ophthalmol. Chic. 1999 Mar; 117 (3): 371–8. doi:10.1001/archopht.117.3.371
4. Singh A.D., Shields C.L., Shields J.A. Von Hippel – Lindau Disease. Surv Ophthalmol. 2001 Sep 1; 46 (2): 117–2. doi:10.1016/s0039-6257(01)00245-4
5. Singh A.D., Nouri M., Shields C.L., Shields J.A., Smith A.F. Retinal capillary hemangioma: a comparison of sporadic cases and cases associated with von Hippel – Lindau disease. Ophthalmology. 2001 Oct. 1; 108 (10): 1907–11. doi:10.1016/s0161-6420(01)00758-8
6. Wittebol-Post D., Hes F.J., Lips C.J. The eye in von Hippel – Lindau disease. Long-term follow-up of screening and treatment: recommendations. J. Intern Med. 1998 Jun; 243 (6): 555–61. doi:10.1046/j.1365-2796.1998.00338.x
7. Von Hippel – Lindau disease: case report of a patient with spontaneous regression of a retinal angioma. Available at: https://www.ncbi.nlm.nih.gov/pubmed/3554423
8. Singh A.D., Shields J.A., Shields C.L. Solitary retinal capillary hemangioma: hereditary (von Hippel-Lindau disease) or nonhereditary? Arch Ophthalmol. 2001 Feb 1; 119 (2): 232–4.
9. Melmon K.L., Rosen S.W. Lindau’s disease: Review of the literature and study of a large kindred. Am. J. Med. 1964 Apr. 1; 36 (4): 595–617. doi: 10.1016/0002-9343(64)90107-x
10. Niemelä M., Lemeta S., Sainio M., et al. Hemangioblastomas of the retina: impact of von Hippel – Lindau disease. Invest Ophthalmol Vis Sci. 2000 Jun.; 41 (7): 1909–15.
11. Webster A.R., Maher E.R., Bird A.C., Gregor Z.J., Moore A.T. A clinical and molecular genetic analysis of solitary ocular angioma. Ophthalmology. 1999 Mar; 106 (3): 623–9. doi: 10.1016/S0161-6420(99)90127-6
12. McCabe C.M., Flynn H.W., Shields C.L., et al. Juxtapapillary capillary hemangiomas. Clinical features and visual acuity outcomes. Ophthalmology. 2000 Dec; 107 (12): 2240–8. doi: 10.1016/s0161-6420(00)00422-x
13. Kreusel K.-M., Bechrakis N.E., Krause L., Neumann H.P.H., Foerster M.H. Retinal angiomatosis in von Hippel – Lindau disease: a longitudinal ophthalmologic study. Ophthalmology. 2006 Aug.; 113 (8): 1418–24. doi:10.1016/j.ophtha.2006.02.059
14. Toy B.C., Agrón E., Nigam D., Chew E.Y., Wong W.T. Longitudinal analysis of retinal hemangioblastomatosis and visual function in ocular von Hippel Lindau disease. Ophthalmology. 2012 Dec.; 119 (12): 2622–30. doi: 10.1016/j.ophtha.2012.06.026
15. Maheshwari A., Newman H., Finger P.T. Ocular Von Hippel – Lindau Disease. In: Khetan V, editor. Intraocular Tumors:145-51. Available at: https://doi.org/10.1007/978-981-15-0395-5_10
16. Singh A.D., Nouri M., Shields C.L., Shields J.A., Perez N. Treatment of retinal capillary hemangioma. Ophthalmology. 2002 Oct.; 109 (10): 1799–806. doi:10.1016/s0161-6420(02)01177-6
17. Lane C.M., Turner G., Gregor Z.J., Bird A.C. Laser treatment of retinal angiomatosis. Eye Lond. Engl. 1989; 3 (Pt 1): 33–8. doi: 10.1038/eye.1989.5
18. Bonnet M., Garmier G. [Treatment of retinal capillary angiomas of von Hippel’s disease]. J. Fr. Ophtalmol. 1984; 7 (8-9): 545–55.
19. Huang C., Tian Z., Lai K., et al. Long-Term therapeutic outcomes of photodynamic therapy-based or photocoagulation-based treatments on retinal capillary hemangioma. Photomed. Laser Surg. 2018 Jan.; 36 (1): 10–7. doi: 10.1089/pho.2017.4296
20. Magee M.A., Kroll A.J., Lou P.L., Ryan E.A. Retinal capillary hemangiomas and von Hippel – Lindau disease. Semin Ophthalmol. 2006 Sep.; 21 (3): 143–50. doi: 10.1080/08820530500350712
21. Seibel I., Cordini D., Hager A., et al. Long-term results after proton beam therapy for retinal papillary capillary hemangioma. Am. J. Ophthalmol. 2014 Aug; 158 (2): 381–6. doi: 10.1016/j.ajo.2014.05.003
22. Kreusel K.M., Bornfeld N., Lommatzsch A., Wessing A., Foerster M.H. Ruthenium-106 brachytherapy for peripheral retinal capillary hemangioma. Ophthalmology. 1998 Aug.; 105 (8): 1386–92. doi: 10.1016/S01616420(98)98017-4
23. Chelala E., Dirani A., Fadlallah A. Intravitreal anti-VEGF injection for the treatment of progressive juxtapapillary retinal capillary hemangioma: a case report and mini review of the literature. Clin. Ophthalmol. Auckl. NZ. 2013; 7: 2143–6. doi: 10.2147/OPTH.S53243
24. Nordstrom–O’Brien M., Luijt R. B. van der, Rooijen E van et al. Genetic analysis of von Hippel – Lindau disease. Hum Mutat. 2010; 31 (5): 521–37. doi:10.1002/humu.21219
25. Haddad N.M.N., Cavallerano J.D., Silva P.S. Von Hippel – Lindau disease: a genetic and clinical review. Semin. Ophthalmol. 2013 Sep 1; 28 (5–6): 377–86. doi: 10.3109/08820538.2013.825281
26. von Buelow M., Pape S., Hoerauf H. Systemic bevacizumab treatment of a juxtapapillary retinal haemangioma. Acta Ophthalmol. Scand. 2007 Feb.; 85 (1): 114–6. doi: 10.1111/j.1600-0420.2006.00825.x
27. Slim E., Antoun J., Kourie H.R., Schakkal A., Cherfan G. Intravitreal bevacizumab for retinal capillary hemangioblastoma: A case series and literature review. Can. J. Ophthalmol. J. Can. Ophtalmol. 2014 Oct.; 49 (5): 450–7. doi: 10.1016/j.jcjo.2014.07.007
28. Albiñana V., Escribano R.M.J., Soler I., et al. Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel – Lindau disease. Orphanet J. Rare Dis. 2017 29; 12 (1): 122. doi:10.1186/s13023-017-0664-7
29. Wong W.T., Liang K.J., Hammel K., Coleman H.R., Chew E.Y. Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel – Lindau disease. Ophthalmology. 2008 Nov.; 115 (11): 1957–64. doi: 10.1016/j.ophtha.2008.04.033
30. Mitropoulos P.G., Chatziralli I.P., Peponis V.G., Tsiotra V.A., Parikakis E.A. Photodynamic therapy for juxtapapillary retinal capillary hemangioma. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971562/
31. Parmar D.N., Mireskandari K., McHugh D. Transpupillary thermotherapy for retinal capillary hemangioma in von Hippel – Lindau disease. Ophthalmic Surg. Lasers. 2000 Aug.; 31 (4): 334–6.
32. Schmidt-Erfurth U.M., Kusserow C., Barbazetto I.A., Laqua H. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology. 2002 Jul. 1; 109 (7): 1256–66. doi: 1016/s0161-6420(02)01059-x
33. Dollfus H., Massin P., Taupin P., et al. Retinal hemangioblastoma in von Hippel – Lindau disease: a clinical and molecular study. Invest. Ophthalmol. Vis. Sci. 2002 Sep. 1; 43 (9): 3067–74.
34. Peyman G.A., Rednam K.R., Mottow-Lippa L., Flood T. Treatment of large von Hippel tumors by eye wall resection. Ophthalmology. 1983 Jul.; 90 (7): 840–7. doi: 10.1016/s0161-6420(83)34481-x
35. Wong W.T., Agrón E., Coleman H.R., et al. Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel – Lindau disease. Ophthalmology. 2008 Jan.; 115 (1): 181–8. doi: 10.1016/j.ophtha.2007.03.009
36. De Laey J.J., Hanssens M. Retinal angiomatosis – von Hippel – Lindau’s Disease. In: De Laey J.J., Hanssens M., eds. Vascular tumors and malformations of the ocular fundus. Available at: https://doi.org/10.1007/978-94-009-0589-4_2
37. Vail D. Angiomatosis retinae, eleven years after diathermy coagulation. Am. J. Ophthalmol. 1958 Oct.; 46 (4): 525–34. doi: 10.1016/0002-9394(58)91132-2
38. Sigelman J. Retinal diseases. Pathogenesis, laser therapy and surgery. Boston: Little, Brown and Company; 1984.
39. Active-Surveillance-Guidelines. Available at: https://www.vhl.org/wp-content/uploads/2017/07/Active-Surveillance-Guidelines.pdf
40. Ruppert M.D., Gavin M., Mitchell K.T., Peiris A.N. Ocular manifestations of von Hippel-Lindau Disease. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776162/
41. Binderup M.L.M., Stendell A.-S., Galanakis M., et al. Retinal hemangioblastoma: prevalence, incidence and frequency of underlying von Hippel – Lindau disease. Br. J. Ophthalmol. 2018; 102 (7): 942–7. doi: 10.1136/bjophthalmol-2017-310884
42. Lamiell J.M., Salazar F.G., Hsia Y.E. von Hippel – Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore). 1989 Jan; 68 (1): 1–29. doi:10.1097/00005792-198901000-00001
43. Ridley M., Green J., Johnson G. Retinal angiomatosis: the ocular manifestations of von Hippel – Lindau disease. Can. J. Ophthalmol. 1986 Dec; 21 (7): 276–83.
44. Garcia-Arumí J., Sararols L.H., Cavero L., Escalada F., Corcóstegui B.F. Therapeutic options for capillary papillary hemangiomas. Ophthalmology. 2000 Jan.; 107 (1): 48–54. doi: 10.1016/s0161-6420(99)00018-4
45. McDonald H.R., Schatz H., Johnson R.N., et al. Vitrectomy in eyes with peripheral retinal angioma associated with traction macular detachment. Ophthalmology. 1996 Feb.; 103 (2): 329–35. doi: 10.1016/s0161-6420(96)30696-9
Review
For citations:
Garg G., Finger P.T. Visual prognosis based staging for retinal capillary hemangioma. Russian Ophthalmological Journal. 2020;13(2):12-17. https://doi.org/10.21516/2072-0076-2020-13-2-12-17
Views:
1103
Email this article 